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Abstract
Background: Patients with prosthetic heart valves are a challenge to any anesthesiologist due to
the risk of infective endocarditis, bleeding and thrombosis.
Case presentation: We present anesthetic management of a 58-year-old Indian lady with a
prosthetic (mechanical) heart valve who underwent hemireplacement arthroplasty.
Conclusion: Patients with prosthetic heart valves, especially those with the mechanical valves are
prone for thrombosis and resultant complications if anticoagulation is not maintained properly.
However, when they are scheduled for major surgery, they can be best managed by normalising
the coagulation profile immediately prior to surgery and restarting the anticoagulation as early as
possible.
Background
Management of patients with prosthetic heart valves for
non-cardiac surgery involves cardiac assessment for valvu-
lar function, residual pathology, infective endocarditis
and functional status; assessment of the status of antico-
agulation, any risk of bleeding, preparation for reversal of
anticoagulants if needed intraoperatively; and neurologi-
cal evaluation for detecting any impairment due to throm-
boembolism. We present successful anesthetic
management of a lady with prosthetic mitral and aortic
valves who underwent hemireplacement arthroplasty of
her right hip.
Case presentation
A 58-year-old Indian lady, a known case of rheumatic
heart disease since the age of 16 years who had undergone
a successful mitral and aortic valve replacement surgery 11
years previously, sustained a fall and fractured the neck of
her right femur. She was scheduled for hemireplacement
arthroplasty. She had not sustained any head injury dur-
ing the fall. She was a known diabetic on insulin therapy.
Her past history revealed that prior to the valve replace-
ment, she used to get breathless even while doing routine
daily activities. Presently, she could climb two flights of
stairs without any syncope, palpitations, fatigue, chest
pain or breathlessness prior to the trauma. She was receiv-
ing oral warfarin 2 mg once daily.
Physical examination revealed her to be afebrile, with an
irregularly irregular pulse-104 beats per minute, respira-
tory rate 18 breaths per minute and blood pressure 160/
86 mmHg. Her systemic examination did not reveal any
pathology. Patient's electrocardiogram showed atrial
fibrillation with a heart rate of 110 per minute. Her ECHO
showed 54% ejection fraction, normally functioning
valves, no paravalvular leak and confirmed absence of
vegetations and clots. The chest X ray revealed ball in cage
mitral valve prosthesis, an aortic prosthesis, sternotomy
sutures and cardiomegaly (Fig 1). Her preoperative labo-
ratory evaluation reports are given in Table 1.
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We advised the patient to discontinue warfarin for four
days and started on unfractionated heparin 4000 IU sub-
cutaneously 6th hourly. On the day of surgery, the last
dose of heparin was administered 6 h prior to surgical
incision and the coagulation studies prior to starting the
surgery revealed PT 16 (patient) and 14 (control) with a
INR 1.1, APTT 32 (patient) and 28 (control). Two units of
packed red blood cells were cross matched in view of ane-
mia. Fresh frozen plasma and protamine were reserved for
emergency use in case of undue blood loss during the sur-
gery. Her morning dose of insulin was skipped and she
was kept fasting as per the standard guidelines. She
received ampicillin 1.5 g and gentamicin 80 mg intrave-
nously as infective endocarditis prophylaxis 30 minutes
prior to skin incision.
As the patient was not willing for a regional anesthetic,
general anesthesia was planned. Anesthesia was main-
tained intraoperatively with intravenous infusion of fen-
tanyl 1 μg per minute and isoflurane in a mixture of
oxygen and nitrous oxide. Neuromuscular blockade was
maintained with vecuronium. The process of cementing
was uneventful. The operation resulted in 300 ml blood
loss which was replaced with one unit of packed red blood
cells and crystalloids. Anesthesia was smooth and une-
ventful. After tracheal extubation, the patient was shifted
to high dependency unit for monitoring.
Six hours from the last dose of infective endocarditis
administration, the second dose of ampicillin 1.5 g was
administered in the postoperative period to the patient.
Four hours after the surgery, as the drains did not show
any undue bleeding, it was decided to administer her next
dose of unfractionated heparin. From next day morning,
she was also started on warfarin and PT and APTT were
repeated daily. By fourth day the INR was 3.0, heparin was
stopped and warfarin continued as before and an ECHO
was done which revealed normal functioning valves with
no clot or vegetation. Now, ten days after the procedure,
she is ready to be discharged home.
Discussion
Patients with mechanical prosthetic heart valves are
exposed to a significant threat of thromboembolism and
valve dysfunction if proper anticoagulation is not
achieved. Patients with new generation prosthetic
mechanical mitral valves should receive warfarin to a tar-
Table 1: Laboratory evaluation reports
Hemoglobin 9.3 g/dL
Hematocrit 27.3
Total leucocyte count, differential count 6500, neutrophils 60%, lymphocytes 28%, monocytes 7%, eosinophils 4%, basophils 1%
Fasting blood sugar 103 mg/dL
Blood urea 28 mg/dL
Serum creatinine 0.9 mg/dL
Serum electrolytes Na+ 139 mEq/L, K+ 3.9 mEq/L
Coagulation profile Platelet count 2.76 lakh/mm3, PT 25 (patient) and 14 (control) with a INR 1.8, APTT 31 (patient) and 28 
(control)
CXR showing cardiomegaly with ball in cage mechanical  prosthesis Figure 1
CXR showing cardiomegaly with ball in cage 
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get INR of 2.5–3.5 and for older types of valves the target
INR should be 3.5–4.5 [1]. However, they may later be
scheduled for elective or emergency non-cardiac proce-
dures. This will be a tricky situation for the anesthesiolo-
gist to face as discontinuation of anticoagulation in the
perioperative period can precipitate life threatening
thromboembolism whereas continuation may cause sig-
nificant bleeding during surgery. The risk of thromboem-
bolism by withholding warfarin in patients with
mechanical valve prostheses with atrial fibrillation is
found to vary between 1% to 20% in various studies [2-6].
The prosthetic valve itself may get occluded by thrombus
in 1–13% cases [7]. There are no large randomized studies
that compare different perioperative anticoagulant regi-
mens for patients with mechanical heart valves undergo-
ing surgery. Because of the high risk of hemorrhage, the
INR should be within the normal range before the proce-
dure. In patients with heart valves, both the European
Society of Cardiology and the Fourth American College of
Chest Physicians Consensus Conference on Antithrom-
botic Therapy have recommended perioperative heparini-
zation to minimize the risk of thrombosis resulting from
the return to a normal INR [8,9].
Oral anticoagulation should be discontinued atleast three
days before any major surgery and as a compromise
between no anticoagulation and intravenous heparin,
subcutaneous conventional heparin or low-molecular-
weight heparin in prophylactic doses is substituted preop-
eratively. A dose of heparin should be given 3–6 h preop-
eratively in patients at high risk of thromboembolic
events and heparin should be restarted as soon as possible
post operatively (preferably within 12 h). Warfarin is
restarted 24 hours postoperatively or when patients can
start oral intake. Heparin should be continued till the INR
is in the therapeutic range for at least 48 h, to enable a
reduction in all the vitamin-K-dependent clotting factors
[10,11].
In emergency surgery, the affect of warfarin needs to be
neutralized by FFP, the dose of which depends upon the
individual and this is titrated till INR < 1.5. In addition to
this, vitamin K may also be given intravenously in small
doses as large doses may lead to resistance to warfarin
when it is restarted following surgery.
Conclusion
We conclude that in patients with mechanical prosthetic
heart valves for major elective surgery like bipolar hemire-
placement arthroplasty, warfarin should be changed to
unfractionated heparin atleast 4–5 days prior to surgery.
INR should be less than 1.5 for proceeding with surgery.
In view of risk of possible thrombosis, unfractionated
heparin should be discontinued 3–6 h prior to surgery
and restarted within 6–12 h of completion of the opera-
tion. Infective endocarditis prophylaxis should be admin-
istered to all patients with prosthetic heart valves.
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